ROCKVILLE, Md., April 18, 2017 /PRNewswire/ -- The PCR testing market is a large and diverse market according to Kalorama Information. The healthcare market research firm said that total PCR market (polymerase chain reaction) was over 9 billion and will exceed 12 billion by 2021. Kalorama focused on both the life science PCR market(research and drug development applications) and clinical PCR market (patient diagnostics) in its three-month long study of the PCR industry. Kalorama Information made its finding in its new report, PCR Market for Life Sciences and Diagnostics (qPCR, dPCR and Other NAAT).
"The life sciences market has been the backbone of the market but ten percent revenue growth per year is attractive for many companies, and there's migration to the clinical sector." said Bruce Carlson, Publisher of Kalorama Information. "Large IVD concerns such as Abbott, Roche sell into clinical laboratory segment, as do mid-size IVDs such as Luminex and Quidel."
The life science market grew steadily for over two decades, although this growth is leveling off now, according to the report. This is a large, diverse market that is now facing competition from next generation sequencing for a number of applications. The clinical polymerase chain reaction and other NAAT market is almost two-thirds of the entire market and will grow at almost ten percent per year. The clinical segment includes both NAAT-based based tests for infectious disease, cancer testing, genetic testing, transplantation diagnostics, and a small segment of other tests. The first and largest segment of the clinical diagnostic market is the infectious disease segment. This large market is continuing to grow, fueled by the introduction of rapid point-of-care or near patient tests, and also by the development of syndromic infectious disease tests.
Example of products on the NAAT market that are sold to clinical labs:
Abbott Diagnostics's m2000 RealTime System includes the m2000sp (for medium throughput sample processing) and the m2000rt (which automates the amplification and detection parts of the qPCR reaction).
Roche's IVD platforms for performing PCR assays including cobas® 6800/8800 Systems, cobas® Liat® System and COBAS® TaqMan® 48
Spartan Bioscience Inc.'s RX CYP2C19 System that tests for a a liver enzyme that acts on 10-15% of drugs
Quidel Corporation's AmpliVue assays, Lyra Real-time PCR assays and Solana System
Luminex Corporation's ARIES® System - A sample to answer real-time PCR platform
